GD BioPharma Secures RMB 50 Million in Series A Financing

In 2023, Tianjin Gudui BioPharma Technology Co., Ltd. raised RMB 50 million in a Series A round. The funding will primarily support platform development and the preparation of IND applications for GD-19 and GD-20.